Evidence map›Paper›PMID 39926484›Full record

ArticleACS omega2025

In Silico Study of Pyrin and 14-3-3 Protein Modulation During FMF and PAAND.

Adrine Paronyan, Nelli Muradyan, Arsen Sargsyan, Vahram Arakelov, Grigor Arakelov, Karen Nazaryan

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Adrine ParonyanInstitute of Molecular Biology of the National Academy of Sciences of the Republic of Armenia (NAS RA), Yerevan 0014, Armenia.ORCID https://orcid.org/0009-0005-9315-6606
Nelli MuradyanInstitute of Molecular Biology of the National Academy of Sciences of the Republic of Armenia (NAS RA), Yerevan 0014, Armenia.
Arsen SargsyanInstitute of Molecular Biology of the National Academy of Sciences of the Republic of Armenia (NAS RA), Yerevan 0014, Armenia.
Vahram ArakelovInstitute of Molecular Biology of the National Academy of Sciences of the Republic of Armenia (NAS RA), Yerevan 0014, Armenia.
Grigor ArakelovInstitute of Molecular Biology of the National Academy of Sciences of the Republic of Armenia (NAS RA), Yerevan 0014, Armenia.ORCID https://orcid.org/0000-0003-3697-4512
Karen NazaryanInstitute of Molecular Biology of the National Academy of Sciences of the Republic of Armenia (NAS RA), Yerevan 0014, Armenia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Familial Mediterranean fever (FMF) is a genetically determined disease transmitted through autosomal recessive inheritance. Recently, a rare but similar disease to FMF, pyrin-associated autoinflammation with neutrophilic dermatosis (PAAND), has been discovered. PAAND is inherited dominantly and is characterized by neutrophilic dermatosis and recurrent fevers. The cause of the disease is point mutations in the MEFV gene. The pyrin protein is a product of this gene and is one of the main factors in the disease's progression. This paper examines the interaction between pyrin and the 14-3-3 protein and screens for modulators affecting their interaction. Regulating this interaction is crucial for understanding the mechanism of FMF development, specifically the disruption of this complexation, which leads to inflammatory responses. The pyrin-14-3-3 interaction is essential for designing potential drugs since weakening this interaction can result in inflammation. This research of in silico experiments identified low molecular weight chemical compounds that have a modulating effect on the tertiary structures of mutant variations of pyrin and 14-3-3 proteins. Studies have identified modulator molecules that interact with the FMF-associated mutant structure of pyrin (M694I) and 14-3-3τ. The chemical compounds that result from this process can be used as modulators and as a potential new basis for the development of therapeutic drugs.

Identifiers

PMID39926484
PMCPMC11799992

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.